Neue Studien: Psoriasis im JDDGhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/page/3/?d=1Neue Studien: Psoriasis im JDDGdeMonozentrische Phase‐IIb‐Studie zur Wirksamkeit von Apremilast beim nummulärem Ekzemhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/monozentrische-phase%E2%80%90iib%E2%80%90studie-zur-wirksamkeit-von-apremilast-beim-nummul%C3%A4rem-ekzem-r194/No abstract supplied.

Weiterlesen

]]>194Sat, 23 Aug 2025 07:41:29 +0000Psoriasis treated with dithranol: a pilot study on in vivo reflectance confocal microscopy.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/psoriasis-treated-with-dithranol-a-pilot-study-on-in-vivo-reflectance-confocal-microscopy-r193/BackgroundThere are only limited histomorphological data on the response of psoriatic skin lesions to topical dithranol. In vivo reflectance confocal microscopy (RCM) in psoriatic skin is highly correlated with histopathological findings and allows non-invasive monitoring of treatment effects on a cellular level.

Patients and methods

Prospective, single-center pilot study at a university-based clinic of dermatology between January 1st and August 30th, 2016. Psoriatic lesions of 20 patients receiving dithranol treatment were assessed by RCM at baseline, day 4 and 8 of treatment.

Results

RCM measurements of psoriatic lesions receiving dithranol treatment revealed epidermal histomorphological changes with a strong median reduction of baseline hyperkeratosis by 45.0% (p < 0.001), acanthosis by 38.2% (p < 0.001), and epidermal thickness by 66.5% (p < 0.001) from baseline until day 8. Moreover, semiquantitative measurements of parakeratosis also showed a significant reduction until day 8 (p < 0.001). Correspondingly, RCM revealed dermal histomorphological changes with a decrease in diameter of dermal papillae by 32.1% (p < 0.001), decrease in diameter of papillary vessels by 16.9% (p = 0.002) and a strong semiquantitative reduction of the inflammatory infiltrate (p < 0.001).

Conclusions

Results from our pilot study indicate that topical dithranol treatment of psoriatic lesions may induce a rapid and marked reduction of pathologic epidermal and dermal RCM features.

Weiterlesen

]]>193Sat, 23 Aug 2025 07:41:29 +0000Routineversorgung von Prurigo nodularis in Deutschland: eine retrospektive Analyse der Krankenakten (ADVANCE PN)https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/routineversorgung-von-prurigo-nodularis-in-deutschland-eine-retrospektive-analyse-der-krankenakten-advance-pn-r162/No abstract supplied.

Weiterlesen

]]>162Thu, 31 Jul 2025 12:43:38 +0000Evaluation of routine care of prurigo nodularis in Germany: retrospective chart review study (ADVANCE PN).https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/evaluation-of-routine-care-of-prurigo-nodularis-in-germany-retrospective-chart-review-study-advance-pn-r161/Background and objectivesKnowledge on patient care gaps of prurigo nodularis (PN) is limited. This retrospective chart review (ADVANCE PN) investigated unmet medical needs and gaps in diagnostics, treatment, and management of patients with PN in routine care in Germany.

Patients and methods

Medical records for adults newly diagnosed with PN between January 2012 and December 2022 from dermatologic clinics and office-based dermatologists were analyzed. Baseline demographics, treatment patterns, diagnostics, symptoms, patient-reported outcomes (PROs), and disease-specific scores are reported.

Results

Records of 363 patients from 42 sites were analyzed. Median age (range) was 67 (19-95) years; most patients were female (61.7%), Caucasian (73.4%), and retired (57.3%). Overall, 209 (62.2%) patients had comorbidities (most common: hypertension [28.3%]). Clinically, most patients had nodules (81.1%) or papules (66.7%). PROs, disease-specific scores, and laboratory assessments were performed for 32 (8.8%), 12 (3.3%), and 71 (19.7%) patients, respectively. Topical corticosteroids (TCS) were the most common overall (90.9%) and first-line therapy (84.9%); for second-line therapy, 'no further treatment' was most commonly documented (58.6%).

Conclusions

The findings of ADVANCE PN indicate a high unmet need in the current state of medical care, evidenced by shortcomings in PRO assessment, PN documentation, and adherence to guidelines on PN.

Weiterlesen

]]>161Thu, 31 Jul 2025 12:43:38 +0000Erkennen – Der klinische Blick auf die kutane Tuberkulosehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/erkennen-der-klinische-blick-auf-die-kutane-tuberkulose-r160/No abstract supplied.

Weiterlesen

]]>160Thu, 31 Jul 2025 12:43:38 +0000Recognising cutaneous tuberculosis.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/recognising-cutaneous-tuberculosis-r159/Weiterlesen

]]>159Thu, 31 Jul 2025 12:43:38 +0000Glutenbedingte Hauterkrankungen: Klinik, Diagnostik und Therapiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/glutenbedingte-hauterkrankungen-klinik-diagnostik-und-therapie-r158/No abstract supplied.

Weiterlesen

]]>158Thu, 31 Jul 2025 12:43:38 +0000Gluten-related skin disorders: clinical presentation, diagnostic and treatments.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/gluten-related-skin-disorders-clinical-presentation-diagnostic-and-treatments-r157/Weiterlesen

]]>157Thu, 31 Jul 2025 12:43:38 +0000A case of successful treatment of nail psoriasis with abrocitinib.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/a-case-of-successful-treatment-of-nail-psoriasis-with-abrocitinib-r156/No abstract supplied.

Weiterlesen

]]>156Thu, 31 Jul 2025 12:43:38 +0000Optimizing biologics for chronic plaque psoriasis: insights on non-medical interruptions of IL-17, IL-12/23, and IL-23 inhibitors.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/optimizing-biologics-for-chronic-plaque-psoriasis-insights-on-non-medical-interruptions-of-il-17-il-1223-and-il-23-inhibitors-r155/Background and objectivesContinuous biologic treatment is recommended for patients with psoriasis; however, treatment interruption in daily practice is inevitable. The impact of treatment interruption is difficult to study in a real-world setting. In Taiwan, biologics are reimbursed by the National Health Insurance for moderate-to-severe psoriasis for a 2-year course, followed by regulatory discontinuation. Thus, our study provides pragmatic data on the impact of the interruption of biologics treatment for non-medical reasons on therapy effectiveness.

Patients and methods

This single-center retrospective cohort study recruited patients who underwent two consecutive 2-year courses of biologics between 2012 to 2021.

Results

A total of 192 treatment courses from 61 patients were analyzed, with secukinumab and ustekinumab being the most frequently administered biologics. Among patients who continued with the same biologic across two consecutive courses, the time to achieve PASI 75 was shorter during the first course compared to the second, while overall maintenance effects remained similar. Switching to a different biologic usually produced superior results in the second course of treatment.

Conclusions

Although the overall effectiveness after interruption and resumption of treatment with secukinumab or ustekinumab was comparable, the time to achieve PASI 75 was longer following an interruption. Continuous, uninterrupted treatment with a given biologic is therefore recommended whenever possible.

Weiterlesen

]]>155Thu, 31 Jul 2025 12:43:38 +0000Secukinumab for erythrodermic psoriasis combined with sepsis: three case reports.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/secukinumab-for-erythrodermic-psoriasis-combined-with-sepsis-three-case-reports-r144/No abstract supplied.

Weiterlesen

]]>144Sat, 12 Jul 2025 18:34:11 +0000Generalized pustular psoriasis in a patient with asthma following dupilumab and tezepelumab therapy.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/generalized-pustular-psoriasis-in-a-patient-with-asthma-following-dupilumab-and-tezepelumab-therapy-r122/No abstract supplied.

Weiterlesen

]]>122Thu, 26 Jun 2025 16:19:30 +0000Verlängerung der Dosierungsintervalle von IL‐17‐ und IL‐23‐Inhibitoren bei erwachsenen Patienten mit Psoriasis: eine Pilotstudie aus der Praxishttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/verl%C3%A4ngerung-der-dosierungsintervalle-von-il%E2%80%9017%E2%80%90-und-il%E2%80%9023%E2%80%90inhibitoren-bei-erwachsenen-patienten-mit-psoriasis-eine-pilotstudie-aus-der-praxis-r85/No abstract supplied.

Weiterlesen

]]>85Sat, 14 Jun 2025 05:52:56 +0000Treatment adjustment in biologic therapies for moderate-to-severe plaque psoriasis: a German retrospective chart review (TABU).https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/treatment-adjustment-in-biologic-therapies-for-moderate-to-severe-plaque-psoriasis-a-german-retrospective-chart-review-tabu-r62/Background and objectivesFlexible biologic therapy dosing regimens in psoriasis management are common, but data from routine care in Germany are scarce. This study evaluated treatment adjustments for biologic therapies commonly prescribed in Germany.

Patients and methods

Charts for up to 100 consecutive patients treated at 29 centers were reviewed. Data were extracted for adults (aged 18-65 years) with moderate-to-severe plaque psoriasis treated with adalimumab, guselkumab, ixekizumab, secukinumab, or ustekinumab for ≥ 36 weeks. The primary endpoint was time to first treatment adjustment. Secondary endpoints included frequency of and reasons for treatment adjustments. Time to treatment adjustment was analyzed using Kaplan-Meier methods.

Results

Among 982 patients, 297 treatment adjustments in 240 (24.4%) patients were identified. The mean (median; interquartile range) time to first treatment adjustment (n = 223) was 8.4 (4.0; 2.0-12.0) months (secukinumab: 14.1 [10.0; 4.0-21.0], adalimumab: 11.0 [7.0; 3.0-14.5], ustekinumab: 11.0 [6.0; 2.0-16.0], ixekizumab: 5.8 [3.0; 2.0-8.5], guselkumab: 5.1 [3.0; 2.0-7.0]). The most frequent adjustment type was starting concomitant treatment(s) (10.4% of patients); insufficient skin effectiveness was the most frequent reason for adjustment.

Conclusions

Biological treatment adjustments are frequent in moderate-to-severe psoriasis; flexible dosing regimens would support optimal management.

Weiterlesen

]]>62Sun, 01 Jun 2025 17:24:13 +0000Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/is-kaposi-sarcoma-a-novel-comorbidity-of-cutaneous-lymphoma-a-systematic-review-of-the-literature-r51/Background and objectivesPatients with cutaneous lymphomas (CL) are at an increased risk of developing secondary malignancies. This study aimed to assess the frequency of association between CL and Kaposi sarcoma (KS) and to identify factors that may promote the co-occurrence of these two diseases.

Patients and methods

On January 25, 2024, we conducted a systematic search of four electronic medical databases to identify all published cases of KS associated with CL. The clinical course and outcomes of these patients were summarized. For critical appraisal, we applied the JBI Checklist for Case Reports. The study was registered in the PROSPERO database (CRD42022313204).

Results

A total of 40 articles reporting on 45 patients were assessed for eligibility. We included 27 cases in the final analysis (26 cutaneous T-cell lymphomas, 1 cutaneous B-cell lymphoma). In 71% of cases, the diagnosis of CL preceded KS. Nearly half (48%) of the patients had erythrodermic mycosis fungoides or Sézary syndrome. KS lesions were predominantly limited to the skin, with complete remission achieved in 53% of cases.

Conclusions

The association between KS and CL is rare, limiting our study due to the small sample size and potential reporting bias. Skin-targeted therapies, a restricted T-cell repertoire, and impaired T-cell responses in erythrodermic CTCL patients may contribute to the development of KS.

Weiterlesen

]]>51Fri, 30 May 2025 15:05:38 +0000Keine orale Beteiligung in einer großen Kohorte von Frauen mit Lichen sclerosus der Vulva – eine multizentrische prospektive Studiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/keine-orale-beteiligung-in-einer-gro%C3%9Fen-kohorte-von-frauen-mit-lichen-sclerosus-der-vulva-eine-multizentrische-prospektive-studie-r50/No abstract supplied.

Weiterlesen

]]>50Fri, 30 May 2025 15:05:38 +0000Klinische und histopathologische Merkmale fortgeschrittener Plattenepithelkarzinome der Haut mit unterschiedlichem Ansprechen auf Cemiplimabhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/klinische-und-histopathologische-merkmale-fortgeschrittener-plattenepithelkarzinome-der-haut-mit-unterschiedlichem-ansprechen-auf-cemiplimab-r49/No abstract supplied.

Weiterlesen

]]>49Fri, 30 May 2025 15:05:38 +0000A novel nomogram to predict psoriatic arthritis in patients with plaque psoriasis.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/a-novel-nomogram-to-predict-psoriatic-arthritis-in-patients-with-plaque-psoriasis-r48/ObjectiveTo construct a predictive model for Psoriatic Arthritis (PsA) based on clinical and ultrasonic characteristics in patients with plaque psoriasis (PsP).

Patients and methods

Demographic, clinical, and ultrasound data were collected from patients with PsP and PsA between May 2019 and December 2022.

Results

A total of 212 patients with PsP and 123 with PsA in the training cohort, whereas the validation cohort comprised 91 patients with PsP and 49 with PsA. The multivariate logistic regression identified nail psoriasis (odds ratio [OR] 1.88, 95% CI: 1.07-3.29), synovitis (OR 18.23, 95% CI: 4.04-82.33), enthesitis (OR 3.71, 95% CI: 1.05-13.14), and bone erosion (OR 11.39, 95% CI: 3.05-42.63) as effective predictors for PsA. The area under the curve was 0.750 (95% CI, 0.691-0.806) and 0.804 (95% CI, 0.723-0.886) for the training and validation cohorts, respectively. The Hosmer-Lemeshow goodness-of-fit test showed good consistency for both the training cohort (p  =  0.970) and the validation cohort (p  =  0.967). Calibration curves also indicated good calibration for both cohorts. The DCA revealed that the predictive model had good clinical utility.

Conclusions

We have developed a quantitative, intuitive, and convenient predictive model based on nail psoriasis, synovitis, enthesitis, and bone erosion to assess the risk of PsA in patients with plaque psoriasis.

Weiterlesen

]]>48Fri, 30 May 2025 15:05:38 +0000Clinicopathological characteristics of low-dose methotrexate-induced epidermal dysmaturation: A study of 22 patients.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/clinicopathological-characteristics-of-low-dose-methotrexate-induced-epidermal-dysmaturation-a-study-of-22-patients-r47/Background and objectiveErosions of the skin and mucous membranes with epidermal dysmaturation are a known side effect of cytostatic chemotherapy regimens and can also be observed during low-dose methotrexate (MTX) therapy. The study aimed to delineate the clinical and histopathological alterations.

Patients and methods

A database search of the archive for dermatopathology was conducted, identifying 22 patients who developed epidermal dysmaturation on low-dose MTX. Clinical and laboratory changes, along with an array of histologic parameters were analyzed and statistically evaluated using SPSS.

Results

Patients were predominantly female with a mean age of 69.1 years. The main indications were psoriasis vulgaris and rheumatoid arthritis. Clinically, patients mostly presented erosive plaques at the injection site, on mucosal surfaces, and disseminated lesions. Most patients showed normal laboratory values. Histopathologically, key findings included enlarged keratinocytes with pale cytoplasm and enlarged nuclei with prominent nucleoli, along with the degeneration of the basal layer. Consistent observations in the dermal compartment included infiltration of neutrophilic granulocytes, lymphocytes, and histiocytes.

Conclusions

This study proposes clinicopathological criteria for the diagnosis of MTX-associated skin toxicity, aiming to increase awareness among clinicians and pathologists for early diagnosis. Early recognition can prevent potentially life-threatening progression.

Weiterlesen

]]>47Fri, 30 May 2025 15:05:38 +0000Therapie eines schweren gemischten Handekzems und generalisierten Ekzems mit dem JAK‐Inhibitor Upadacitinibhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/therapie-eines-schweren-gemischten-handekzems-und-generalisierten-ekzems-mit-dem-jak%E2%80%90inhibitor-upadacitinib-r41/No abstract supplied.

Weiterlesen

]]>41Thu, 29 May 2025 18:10:57 +0000Screening of psoriatic arthritis by dermatologists - a German nationwide survey.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/screening-of-psoriatic-arthritis-by-dermatologists-a-german-nationwide-survey-r40/Background and objectivesUp to 30% of psoriasis (PsO) is clinically associated with psoriatic arthritis (PsA). A large proportion of new onset of PsA is diagnosed at a later stage, despite the necessity of early effective treatment to prevent structural damage. This study aimed to identify the routine screening practices used for PsA in patients with PsO.

Patients and methods

This non-interventional, prospective, epidemiological, cross-sectional study conducted in Germany focuses on screening activity and treatment selection of dermatological practices in suspected PsA. Descriptive statistics and patient characteristics were analyzed for different center types.

Results

One hundred ninety-five patients from 34 office-based physicians, five non-university hospitals, and nine university hospitals were included. Questionnaires or imaging techniques were not routinely used (< 45%). Especially, ultrasounds (≤ 5%) and MRIs (< 6.3%) were rarely performed. Between 30% and 75% of suspected PsA could be confirmed. Referral to rheumatologists and/or appropriate therapy initiation were the most frequent consequences.

Conclusions

Results of this study reflect the status of PsA screening activity by dermatologists. Imaging techniques, particularly ultrasound or MRIs to detect early forms of PsA, were inadequately used, which may have contributed to continued underdiagnoses. Collaboration between dermatologists and rheumatologists should be reviewed with a view to improving effective PsA screening.

Weiterlesen

]]>40Thu, 29 May 2025 18:10:57 +0000Long-term remission and normal pregnancy with successful delivery in a patient with generalized pustular psoriasis after spesolimab.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/long-term-remission-and-normal-pregnancy-with-successful-delivery-in-a-patient-with-generalized-pustular-psoriasis-after-spesolimab-r39/No abstract supplied.

Weiterlesen

]]>39Thu, 29 May 2025 18:10:57 +0000Grover's disease-like patterns in early pityriasis rubra pilaris.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/grovers-disease-like-patterns-in-early-pityriasis-rubra-pilaris-r38/No abstract supplied.

Weiterlesen

]]>38Thu, 29 May 2025 18:10:57 +0000Update Vulvadermatologie – Diagnostik und Therapiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/update-vulvadermatologie-diagnostik-und-therapie-r37/No abstract supplied.

Weiterlesen

]]>37Thu, 29 May 2025 18:10:57 +0000Impact of a dermatological rehabilitation program on cardiovascular risks of psoriasis patients.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/impact-of-a-dermatological-rehabilitation-program-on-cardiovascular-risks-of-psoriasis-patients-r36/Background and objectivesPsoriasis vulgaris is a common chronic inflammatory skin disease, associated with multiple cardiovascular comorbidities, which can ultimately lead to increased mortality. Dermatological rehabilitation programs represent an additional therapeutic option in patients with psoriasis besides the classical outpatient or inpatient management. This study aimed to investigate the impact of dermatological rehabilitation on cardiovascular risk factors, cardiorespiratory fitness and quality of life at the Clinic of Dermatology, Bad Bentheim, Germany.

Patients and methods

This prospective study included 105 patients (age > 18 years) with known psoriasis and/or psoriasis (pustulosa) palmoplantaris committing to a 3-week long rehabilitation program. Various patient reported outcomes including dermatological life and quality index, patient global assessment, physical activity, pruritus and smoking and alcohol consumption history were captured. Body mass index (BMI) and physical fitness were also assessed. Study parameters were collected by telephone at baseline, at discharge, and at 3 and 6 months.

Results

Significant improvements in cardiorespiratory fitness (p < 0.001), BMI (p < 0.001), quality of life (p < 0.001), patients subjective estimation of disease severity (p < 0.001) and psoriasis area and severity index (p < 0.001) were shown.

Conclusions

The findings emphasize the importance of a rehabilitation program for patients with psoriasis due to its positive and sustained effects on cardiovascular risk factors.

Weiterlesen

]]>36Thu, 29 May 2025 18:10:57 +0000